SCHEMBL30962912

SCHEMBL30962912

COc1nc(Nc2ccc(C3CCN(C)CC3)c(C)c2)nc(-c2c(Br)cccc2C#N)c1C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TBK1 Q9UHD2 8/20 0.41
▸ JAK2 O60674 3/20 0.41
▸ ALK Q9UM73 2/20 0.41
▸ EHMT2 Q96KQ7 1/20 0.38
▸ SLC2A1 P11166 1/20 0.38
▸ PKMYT1 Q99640 2/20 0.38
▸ WEE1 P30291 1/20 0.37
▸ CCNT1 O60563 1/20 0.36
▸ CDK1 P06493 1/20 0.36
▸ CCNB1 P14635 1/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CDK7 P50613 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ CCNH P51946 1/20 0.36
▸ MAP4K1 Q92918 2/20 0.35
▸ PTK2 Q05397 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30962716 0.92 ALK (0.43) TBK1JAK2ALKEHMT2WEE1
SCHEMBL30962632 0.91 WEE1 (0.43) TBK1JAK2ALKEHMT2SLC2A1
SCHEMBL30962784 0.90 ALK (0.41) TBK1JAK2ALKEHMT2WEE1
SCHEMBL30962847 0.90 TBK1 (0.42) TBK1JAK2ALKEHMT2SLC2A1
SCHEMBL30962694 0.90 WEE1 (0.44) TBK1JAK2ALKEHMT2SLC2A1
SCHEMBL30962698 0.87 ALK (0.43) TBK1JAK2ALKEHMT2WEE1
SCHEMBL30962797 0.85 WEE1 (0.47) TBK1JAK2ALKEHMT2SLC2A1
SCHEMBL30962700 0.85 WEE1 (0.43) TBK1JAK2ALKEHMT2WEE1
SCHEMBL30962777 0.85 WEE1 (0.46) TBK1JAK2ALKEHMT2SLC2A1
SCHEMBL30962861 0.84 ALK (0.41) TBK1JAK2ALKEHMT2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 — — EP disclosed
WO-2024145505-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS ACRIVON THERAPEUTICS, INC. (US) 2024-07-04 — — WO disclosed
Send feedback